After Dr. Sylke Hassel’s exclusive interview at CPHI Worldwide, Arul Ramadurai, CCO at Axplora, also spoke on camera to share his business vision. This interview takes us on a journey through Axplora’s legacy forged through the integration of Farmabios, Novasep, and Pharmazell, and how this heritage forms the bedrock of Axplora’s commercial strategy.
In essence, the three legacy brands have come together to offer both API products to generic companies and CDMO services to innovative big pharma and biotech companies and thus support the entire lifecycle of pharmaceutical products.
Arul underlines the unbreakable link between patients’ security and our sites’ audits and certifications to meet the customers’ expectations. And for him, security supply, high quality, and products on time are the basics that set Axplora apart as a Reliable Partner.
Last point but not least, Arul provides a glimpse into Axplora’s Environmental, Social, and Governance (ESG) strategy, not only expected by customers but also core to “our being”. Indeed, as a player in the pharmaceutical industry, Axplora is actively looking for more sustainable and cost-efficient solutions such as electrochemistry where the company has gained a unique experience and expertise to match the increased complexity of new APIs being developed.
Latest news
Press Release
September 29, 2026
Axplora launching “Axotecan” to strengthen Global ADC supply
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with validation batches targeted by the end of 2026 and GMP supply planned for late 2027 Cross-business collaboration combines Farmabios’ HPAPI expertise with Novasep CDMO’s integrated ADC capabilities September 29th, 2026 – Axplora, a global manufacturing […]
News
September 25, 2026
Axplora celebrates 60 years of innovation at Chasse-sur-Rhône
More than 300 employees, family members and guests joined the anniversary celebration on Saturday 19 September. Event honors six decades of expertise and the site’s continuing commitment to reliable, responsible manufacturing for customers and patients September 25, 2026 – Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has marked 60 […]
News
August 05, 2026
Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network
Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. July 2026 – Axplora, a […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.